Ulocuplumab (3-30 mg/kg; i.p.; every 3-4 days for 5 doses; 65 days in total) inhibits tumor growth of multiple myeloma xenograft models in mice, including Ramos B cells, HL-60 cells, MOLP-8 cells, Nomo-1 cells, and JJN-3R cells models[1].
| Animal Model: | Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1] |
| Dosage: | 3-30 mg/kg |
| Administration: | Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days |
| Result: | Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25. |
